UCB announces U.S. FDA approval of ZILBRYSQ[®] for the treatment of adults with generalized myasthenia gravis FDA approval of ZILBRYSQ® has been granted.
Zilucoplan is the first once-daily, subcutaneous, self-administered, targeted C5 complement inhibitor for adults with gMG who are AChR antibody positive.
FDA approval of ZILBRYSQ® has been granted for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody-positive1ZILBRYSQ is the first.